2 unchanged sentences
We have never declared or paid dividends on our capital stock and do not anticipate paying any dividends in the foreseeable future.
−Removed: Selected Financial Data
−Removed: Selected Consolidated Financial Data
−Removed: (in thousands, except per share data)
−Removed: The data set forth below should be read in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in Item 7 and the Consolidated Financial Statements and related Notes included in Item 8 of this Report.
−Removed: Year Ended December 31,
−Removed: Consolidated Statements of Operations Data:
−Removed: Product revenues, net (1)
−Removed: Product royalty revenues (2)
−Removed: Milestone and contract revenues (3)
−Removed: Other revenues
−Removed: Total revenues
−Removed: Costs and expenses:
−Removed: Cost of product revenues (including definite-lived intangible amortization)
−Removed: Research and development (4)
−Removed: Selling, general and administrative (4)
−Removed: Change in fair value of acquisition-related contingent consideration
−Removed: Collaboration loss sharing
−Removed: Total costs and expenses
−Removed: Income (loss) from operations
−Removed: Other income (expense), net (4)
−Removed: Interest expense
−Removed: Unrealized gain (loss) on long term investment
−Removed: Expense related to senior note conversions
−Removed: Income (loss) before provision for income taxes
−Removed: Provision for income taxes
−Removed: Net income (loss)
−Removed: Net income (loss) per share:
−Removed: Shares used in computing net income (loss) per share:
−Removed: (1) 2020 product revenues, net, include our product sales of JAKAFI, ICLUSIG and PEMAZYRE.
−Removed: 2019, 2018, 2017 and 2016 product revenues, net, relate to our product sales of JAKAFI and ICLUSIG from the date of acquisition on June 1, 2016.
−Removed: (2) 2020 product royalty revenues relate to Novartis net sales of TABRECTA worldwide, Novartis net sales of JAKAVI outside of the United States and Lilly net sales of OLUMIANT outside of the United States.
−Removed: 2019, 2018 and 2017 product royalty revenues relate to Novartis net sales of JAKAVI outside of the United States and Lilly net sales of OLUMIANT outside of the United States.
−Removed: 2016 product royalty revenues relate to Novartis net sales of JAKAVI outside the United States.
−Removed: (3) 2020 milestone and contract revenues relate to our collaborative research and license agreements with Novartis, Lilly and Innovent.
−Removed: 2019 milestone and contract revenues relate to our collaborative research and license agreements with Innovent and Zai Lab.
−Removed: 2018, 2017 and 2016 milestone and contract revenues relate to our collaborative research and license agreements with Novartis and Lilly.
−Removed: (4) Upon the retrospective adoption of ASU No.
−Removed: 2017-07 on January 1, 2018, the presentation of other components of net periodic benefit cost were reclassed out of operating income and into other income (expense), net for the periods presented, as applicable.
−Removed: Consolidated Balance Sheets Data:
−Removed: Cash, cash equivalents, and marketable securities
−Removed: Working capital
−Removed: Total assets (1)
−Removed: Convertible senior notes
−Removed: Stockholders’ equity
−Removed: (1) On January 1, 2019, we adopted ASU No.
−Removed: 2016-02 which required us to recognize lease right-of-use assets and corresponding lease liabilities on the consolidated balance sheet.
−Removed: No prior periods were restated as further discussed in Note 1 of Notes to the Consolidated Financial Statements.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.